Physician profile
Sameer M Ankolkar
NPI 1417924119
$1,569.25
in general payments reported to CMS, 2019-2025
21 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $254 · 2023: $344 · 2024: $364 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $320.70 | 2022-2025 | Vraylar, Creon, Viberzi |
| Astrazeneca Pharmaceuticals LP | $154.08 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $134.62 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $125.30 | 2023-2025 | |
| Lilly USA, LLC | $115.79 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $104.24 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.73 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $61.50 | 2022-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $58.17 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $57.61 | 2022 | |
| Exact Sciences Corporation | $49.03 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $46.16 | 2022-2023 | Xarelto, Spravato |
| Amgen INC. | $44.16 | 2022-2025 | Repatha, Otezla |
| Abbott Laboratories | $42.43 | 2024-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $40.85 | 2022-2023 | Eliquis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $35.97 | 2023-2024 | |
| Astellas Pharma US INC | $27.03 | 2025 | Veozah |
| Axsome Therapeutics, INC. | $22.61 | 2025 | Auvelity |
| Actelion Pharmaceuticals US, INC. | $20.52 | 2025 | Uptravi, Opsumit |
| Collegium Pharmaceutical, INC. | $16.25 | 2025 | Jornay Pm |
| Biohaven Pharmaceutical Holding Company LTD. | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Ankolkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.